viewTissue Regenix Group PLC

Tissue Regenix says sales and earnings in-line; looking for additional sources of funding

The regenerative medicines specialist said it has £2.4mln of cash, including a £1mln revolving credit facility. This, it added, was enough to see it through to “at least the end of April”

Tissue Regenix Group PLC -

Tissue Regenix PLC (LON:TRX) said it expects to report sales and earnings (EBITDA) in line with revised expectations as it re-confirmed it is looking for sources of additional finance for the regenerative medicines business.

Revenues for the year gone rose 12% to £13mln, the company said in a comprehensive trading update, which also revealed it had £2.4mln of cash, including a £1mln revolving credit facility. This, Tissue Regenix said, was enough to see it through to “at least the end of April”.

The headwinds facing the company have been well flagged. In September it said it had been held back by “limited availability of donor material together with poorer yields, which impacted second-half product availability and sales performance”.


A restructuring has seen a reduction in headcount by 18, while investment in plant facilities has increased both throughput and utilisation.

Talks with potential funders of business are continuing, Tissue Regenix confirmed.

Chairman John Samuel said: "During 2019, the company has faced various operational challenges. However, we have increased utilisation and throughput of our US facility to meet the expected increase in demand for our products.

“Through both organic growth and collaboration with strategic partners, we remain confident in our ability to reach profitability, once our new facility becomes available."

Quick facts: Tissue Regenix Group PLC

Price: 0.3391 GBX

Market: AIM
Market Cap: £23.85 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...


Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

2 min read